Dr. Jun Guo: Reflecting on Progress in Renal Cancer Treatment and Pioneering a New Era of Cellular Therapy for Metastatic Patients

Dr. Jun Guo: Reflecting on Progress in Renal Cancer Treatment and Pioneering a New Era of Cellular Therapy for Metastatic Patients

2024.11.25
Renal cancer is one of the three major malignancies in the urinary system, with advanced metastatic renal cancer having a poor prognosis and an overall five-year survival rate of less than 20%. Recent advances in targeted therapies and immunotherapies have led to significant improvements in treatment outcomes; however, for patients progressing beyond first-line therapies, the quest to extend survival remains an ongoing challenge. At the recently held 8th West China Uro-Oncology Tianfu Academic Conference, Dr. Jun Guo from Peking University Cancer Hospital shared insights into "Future Trends in Cellular Therapy for Renal Cancer," offering new hope for these patients. Following the conference, Oncology Frontier invited Professor Guo to provide further insights.
Strengthening Global Bonds in Cancer Control: Highlights from the CACA-SLACOM and CACA-SIS Summits

Strengthening Global Bonds in Cancer Control: Highlights from the CACA-SLACOM and CACA-SIS Summits

2024.11.25
The 2024 Chinese Congress of Holistic Integrative Oncology (CCHIO) and the 4th Asian Oncology Summit (AOS), hosted by the Chinese Anti-Cancer Association (CACA) in collaboration with the Chinese Academy of Integrative Medicine and the Shaanxi Anti-Cancer Association, took place from November 14–17 in the ancient city of Xi'an. This prestigious event featured specialized summits co-organized by CACA and global cancer organizations, including the National Comprehensive Cancer Network (NCCN), Union for International Cancer Control (UICC), Society of Latin American and Caribbean Oncology (SLACOM), and International Society of Breast Disease (SIS), to foster international collaboration in cancer prevention and treatment.
ESMO 2024丨Dr. Antonio Passaro: Zipalertinib Shows Promising Efficacy and Safety in EGFR Exon 20 Insertion-Mutant NSCLC Patients

ESMO 2024丨Dr. Antonio Passaro: Zipalertinib Shows Promising Efficacy and Safety in EGFR Exon 20 Insertion-Mutant NSCLC Patients

2024.11.24
The 2024 European Society for Medical Oncology (ESMO) Annual Meeting was held from September 13 to 17 in Barcelona, Spain, where several significant advances in lung cancer research were presented. Dr. Antonio Passaro from the European Institute of Oncology Division of Thoracic Oncology in Milan, Italy, shared insights on the safety and antitumor activity of Zipalertinib in previously treated NSCLC patients with EGFR exon 20 insertion mutations. Oncology Frontier had the opportunity to interview Professor Passaro on-site, where he discussed the latest advances in EGFR-targeted therapies.
Dr. Jin Yang: Advancing Quality Control in Breast Cancer Care—Insights into National Performance Indicators and Challenges

Dr. Jin Yang: Advancing Quality Control in Breast Cancer Care—Insights into National Performance Indicators and Challenges

2024.11.22
Editorial Note: Quality control has become an increasingly critical focus in breast cancer diagnosis and treatment. As China enhances its cancer prevention and control framework, the standardization of breast cancer care is receiving growing attention. At the 2024 Conference on Standardized Diagnosis and Quality Control in Breast Cancer, Dr. Jin Yang from The First Affiliated Hospital Xi'an Jiao Tong University presented a comprehensive report titled Quality Control in Breast Cancer Care and National Performance Indicators. In an exclusive interview with Oncology Frontier, Professor Yang provided in-depth insights into the content, significance, and implementation challenges of these quality control measures, illuminating the path forward for breast cancer diagnosis and treatment in China.
CCHIO 2024丨Dr. Jin Zhang: Achievements of CBCS Over 38 Years and Advances in HR+ Breast Cancer Precision Diagnosis and Treatment

CCHIO 2024丨Dr. Jin Zhang: Achievements of CBCS Over 38 Years and Advances in HR+ Breast Cancer Precision Diagnosis and Treatment

2024.11.22
From November 15 to 17, 2024, the Chinese Congress on Holistic Integrative Oncology (CCHIO)(CCHIO) was held in Xi’an under the theme "Winning in Integration: Tumor Prevention and Treatment." In the breast cancer domain, the conference integrated the latest global advancements in diagnosis, treatment, and research. At the event, Oncology Frontier interviewed Dr. Jin Zhang, Chair of The Chinese Anti-Cancer Association, Committee of Breast Cancer Society (CACA-CBCS) and a renowned expert from Tianjin Medical University Cancer Institute and Hospital. Professor Zhang shared her insights into the development of breast oncology in China, focusing on HR-positive breast cancer, and discussed the current landscape and future of precision diagnosis and treatment in this area.
The 9th Congress of the CCIHPBA | Prof. Chaoliu Dai: Revisiting Hemorrhage Control and Residual Liver Function Protection in Hepatectomy

The 9th Congress of the CCIHPBA | Prof. Chaoliu Dai: Revisiting Hemorrhage Control and Residual Liver Function Protection in Hepatectomy

2024.11.20
At the recent The 9th Congress of the Chinese Chapter of the International Hepato-Pancreato-Biliary Association (CCIHPBA), Prof. Chaoliu Dai from Shengjing Hospital of China Medical University presented on “Controlling Intraoperative Hemorrhage and Protecting Residual Liver Function in Hepatectomy.” Oncology frontier invited Prof. Dai to delve further into this topic and share insights from his presentation.